DEVELOPMENTAL CHEMOTHERAPY

发育期化疗

• 批准号: 6664387
• 负责人: DAVID R SPRIGGS
• 金额: $ 18.86万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-07-01 至 2003-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6664387
• 关键词: amidohydrolases; antineoplastics; arsenic; clinical trial phase I; drug design /synthesis /production; enzyme inhibitors; human subject; human therapy evaluation; neoplasm /cancer; neoplasm /cancer chemotherapy; patient oriented research; pharmacokinetics

DESCRIPTION: (Applicant's Description) Chemotherapy remains one of the principal means of cancer treatment. Over the past 3 decades, this grant has allowed Memorial Hospital to rapidly test and apply new treatments to a variety of cancers. The overall goal of this project will be to conduct Phase I studies of new single agents and combination therapies developed at Memorial Hospital for application in disease specific Phase II and Phase III trials. Highest priority for new studies will be given to ideas and compounds developed within the Memorial Sloan Kettering Cancer Center for which we hold the IND. The clinical trials to be performed will include both molecular markers of response and pharmacokinetics when appropriate. All trials in this project are Phase I studies. The clinical trials performed in this project will be grouped into 3 specific aims. Specific aim 1 is the development of novel agents including geldanamycin analogs, 10 - propargyl-10 deazaaminopterin, arsenic trioxide, PS341, and desoxyepothilone B. Specific Aim Two is a target based therapy program utilizing Pyroxamide and is directed at the development of this putative differentiation agent. Finally, in Specific aim 3 correlative science is described to support these trials. Each of these clinical studies will be linked to pharmacokinetic and molecular laboratory correlative studies. Through this work, we expect to identify new, more active treatments for the successful management of human malignancies.

描述：（申请人的描述）化疗仍然是治疗方法之一 癌症治疗的主要手段。过去 3 年来，这笔赠款已 允许纪念医院快速测试新疗法并将其应用于 各种癌症。该项目的总体目标是进行阶段 我对纪念馆开发的新单药和联合疗法进行研究 医院用于特定疾病的 II 期和 III 期试验的应用。 新研究的最高优先级将放在想法和化合物上 在我们举办的纪念斯隆凯特琳癌症中心内开发 IND。要进行的临床试验将包括分子 适当时反应和药代动力学的标志物。本次所有试验 项目是第一阶段研究。本项目进行的临床试验 将分为 3 个具体目标。具体目标1是发展 新型药物，包括格尔德霉素类似物，10-propargyl-10 脱氮氨基蝶呤、三氧化二砷、PS341 和脱氧埃坡霉素 B. 特异性 目标二是一个利用 Pyroxamide 的基于目标的治疗计划，旨在 开发这种假定的分化剂。最后，在 具体目标 3 描述了相关科学来支持这些试验。每个 这些临床研究中的一部分将与药代动力学和分子生物学相关 实验室相关研究。通过这项工作，我们希望发现新的、 成功治疗人类恶性肿瘤的更积极的治疗方法。